Cantor Fitzgerald Initiates Coverage On 4D Molecular Therapeutics with Overweight Rating, Announces Price Target of $32
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has initiated coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with an Overweight rating and a price target of $32.
October 24, 2023 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has initiated coverage on 4D Molecular Therapeutics with an Overweight rating and a price target of $32.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for 4D Molecular Therapeutics. The price target of $32 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100